Nektar Therapeutics

NKTR remains in a healthy Stage 2 uptrend above its 200‐day SMA with higher highs and lows, currently experiencing a volume‐light pullback into rising EMAs and the 50 SMA. Short‐term exhaustion and neutral RSI suggest patience, while the medium‐term bias stays bullish. Preferred engagement is on pullback acceptance around $70–72 or upon a sustained reclaim of the 9/20 EMAs.

• ↑Phase 2b REZOLVE-AD results indicate strong rezpegaldesleukin efficacy in moderate-to-severe atopic dermatitis.
• ↑A $1B cash and securities balance funds R&D and phase 3 trials through 2027.
• ↓Shares outstanding jumped from 14.1m to 33.1m, raising significant dilution concerns.